Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zishen Yutai Pill is a Traditional Chinese Medicine (TCM) formula developed to tonify the kidney, nourish the blood, and support fetal stability. It is widely utilized in reproductive medicine as an adjuvant therapy for women undergoing assisted reproductive technologies (ART), such as in vitro fertilization-embryo transfer (IVF-ET). The pill is composed of multiple herbal ingredients, including *Cuscuta chinensis*, *Dipsacus asper*, *Taxillus chinensis*, *Panax ginseng*, and *Colla Corii Asini*. Clinical research indicates that Zishen Yutai Pill may improve clinical pregnancy rates and live birth rates by enhancing endometrial receptivity, regulating the hypothalamic-pituitary-ovarian (HPO) axis, and improving ovarian response in patients with diminished ovarian reserve (DOR) or recurrent implantation failure (RIF). It is also investigated for its role in preventing preeclampsia and treating polycystic ovary syndrome (PCOS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zishen Yutai Pill.